Table 2.
Baseline characteristics of pneumonia patients with different COVID-19 types
| Characteristics | Critical (N = 24) | Severe (N = 26) | Moderate (N = 48) | p value |
|---|---|---|---|---|
| Age, years | 71.3±8.58 | 68.56±12.26 | 64.85±11.81 | 0.07 |
| Gender | ||||
| Male | 18 (75) | 17 (65.38) | 29 (60.42) | 0.47 |
| Female | 6 (25) | 9 (34.62) | 19 (39.58) | |
| BMI, kg/m2 | 21.65±1.16 | 23.64±5.04 | 23.1±4.3 | 0.61 |
| Smoking history | 0 (0) | 2 (7.69) | 3 (6.25) | 0.41 |
| Kidney disease | ||||
| Chronic nephritis | 4 (16.67) | 7 (26.92) | 13 (27.08) | 0.59 |
| Diabetes nephropathy | 11 (45.83) | 11 (42.31) | 15 (31.25) | 0.41 |
| Hypertensive nephropathy | 4 (16.67) | 4 (15.38) | 14 (29.17) | 0.29 |
| Obstructive nephropathy | 1 (4.17) | 1 (3.85) | 2 (4.17) | 1.00 |
| Lupus nephritis | 1 (4.17) | 1 (3.85) | 0 (0) | 0.37 |
| Polycystic kidney disease | 2 (8.33) | 1 (3.85) | 2 (4.17) | 0.71 |
| Others | 1 (4.17) | 1 (3.85) | 2 (4.17) | 1.00 |
| Comorbidity | ||||
| Hypertension | 18 (75) | 23 (88.46) | 46 (95.83) | 0.03 |
| Coronary heart disease | 13 (54.17) | 15 (57.69) | 27 (56.25) | 0.97 |
| Cerebral infarction | 9 (37.5) | 6 (23.08) | 13 (27.08) | 0.50 |
| Cerebral hemorrhage | 0 (0) | 1 (3.85) | 3 (6.25) | 0.45 |
| Diabetes | 14 (58.33) | 16 (61.54) | 20 (41.67) | 0.19 |
| Chronic obstructive pulmonary disease | 1 (4.17) | 2 (7.69) | 2 (4.17) | 0.78 |
| Vaccine administration | 0.10 | |||
| No | 15 (62.5) | 23 (88.46) | 35 (72.92) | |
| Yes | 9 (37.5) | 3 (11.54) | 13 (27.08) | |
| Cancer history | 0 (0) | 1 (3.85) | 4 (8.33) | 0.30 |
| With non-pulmonary infection | 6 (25) | 2 (7.69) | 2 (4.17) | 0.02 |
| Symptom | ||||
| Fever | 15 (62.5) | 9 (34.62) | 23 (47.92) | 0.14 |
| Low-grade fever (<38°C) | 2 (8.33) | 2 (7.69) | 5 (10.42) | 0.97 |
| Moderate-grade fever (38–39°C) | 9 (37.5) | 5 (19.23) | 13 (27.08) | |
| High-grade fever (39–41°C) | 4 (16.67) | 2 (7.69) | 5 (10.42) | |
| Sore throat | 2 (8.33) | 1 (3.85) | 1 (2.08) | 0.45 |
| Cough/sputum | 17 (70.83) | 24 (92.31) | 34 (70.83) | 0.09 |
| Nasal congestion/runny nose | 1 (4.17) | 1 (3.85) | 6 (12.5) | 0.31 |
| Headache | 1 (4.17) | 2 (7.69) | 7 (14.58) | 0.34 |
| Muscle/joint pain | 14 (58.33) | 10 (38.46) | 23 (47.92) | 0.37 |
| Fatigue | 5 (20.83) | 6 (23.08) | 6 (12.5) | 0.45 |
| Abdominal pain/diarrhea | 8 (33.33) | 0 (0) | 13 (27.08) | 0.01 |
| Decreased sense of smell and taste | 17 (70.83) | 17 (65.38) | 33 (68.75) | 0.91 |
| Chest tightness/shortness of breath | 17 (70.83) | 20 (76.92) | 32 (68.09) | 0.73 |
| Nausea | 1 (4.17) | 2 (7.69) | 6 (12.77) | 0.47 |
| Altered mental status | 4 (16.67) | 2 (7.69) | 2 (4.26) | 0.20 |
| Chest CT | 0.37 | |||
| Unilateral involvement | 0 (0) | 1 (3.85) | 0 (0) | |
| Bilateral involvement | 13 (54.17) | 18 (69.23) | 34 (70.83) | |
| Extensive ground-glass opacity with consolidation, linear, or reticular opacity | 10 (41.67) | 5 (19.23) | 12 (25) | |
| Diffuse consolidation with ground-glass opacity | 1 (4.17) | 2 (7.69) | 2 (4.17) | |
Data were reported as mean ± standard deviation (SD) or number (percentage) as appropriate.
Comparison was conducted among patients with a different severity.